E

Edwards Lifesciences

Develops transcatheter heart valves and devices

Director HR Business Leader

Full-Time
No salary listed
Expert
Bachelor's, Master's
Draper, UT, USA
In PersonThe role is fully in person in Draper, Utah.
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • A bachelor's degree in a related field or equivalent work experience based on Edwards criteria is required.
  • Previous related human resources experience or equivalent work experience based on Edwards criteria is required.
  • A demonstrated track record in people management or equivalent work experience based on Edwards criteria is required.
Responsibilities
  • Lead, direct, evaluate, and develop a team of human resources professionals to implement HR strategy, manage budgets, and comply with regulations, laws, and employment standards.
  • Develop a talent development plan aligned with the department's functional growth strategies.
  • Act as a strategic thought partner for assigned client groups, countries, and/or regions to develop and implement human resources strategies that achieve business objectives.
  • Partner with HR management or Centers of Excellence to evaluate future workforce needs, recommend HR strategy changes, and adapt HR programs.
  • Advise, influence, and partner with leadership on talent strategies and actions to build organizational capabilities and an engaged, high-performing organization.
  • Lead or partner with Centers of Excellence to deliver human resources programs for client groups and meet current and future talent requirements.
  • Participate in interviewing and selecting talent in assigned client groups and perform compensation analysis to support competitive offers.
  • Analyze trends and metrics to identify training and individual executive coaching needs, develop solutions with Centers of Excellence or Shared Services, and participate in evaluating and monitoring training and coaching programs.
  • Represent leadership on projects across multiple areas while interfacing with project managers, the human resources team, and middle management.
  • Consult in project settings across multiple human resources areas while interfacing with low- to middle-management personnel.
  • Provide human resources leadership to outsourcing partners at the task level and participate in small-scale requests for proposals.
  • Follow company rules and requirements, including pandemic protocols and Environmental Health and Safety rules, and take control measures to prevent injuries and environmental pollution.
Desired Qualifications
  • A master's degree or equivalent in a related field or equivalent work experience based on Edwards criteria.
  • Certification in a related discipline, such as Professional in Human Resources, Senior Professional in Human Resources, or Global Professional in Human Resources.
  • Proven project management skills.
  • Expertise in Microsoft Office Suite and human resources systems.
  • Facilitation and presentation skills.
  • Problem-solving, organizational, analytical, and critical-thinking skills.
  • Written and verbal communication and interpersonal relationship skills, including influencing, consultative, and relationship-management skills.
  • Expertise in the relevant human resources sub-functions or areas and broad advanced knowledge of the organization's work area.
  • Expert understanding of related human resources processes and systems.
  • Expert knowledge of legal requirements for day-to-day employee management, legal-risk reduction, and regulatory compliance.
  • Expert knowledge of local and federal employment laws in one or more areas.
  • Negotiation and conflict-resolution skills.
  • Leadership skills and the ability to influence change.
  • Ability to build and maintain strong organizational relationships.
  • Business literacy regarding the client group's business, financial position, midrange plans, culture, and competition.
  • Ability to interact professionally with all organizational levels while establishing a positive reputation.
  • Ability to navigate challenging forces in a fast-paced and dynamic environment.

About the company

Edwards Lifesciences focuses on cardiovascular medical technologies, especially transcatheter heart valves. Its products enable repairing or replacing diseased heart valves through minimally invasive procedures rather than open-heart surgery. The company builds on a long history that began with the Starr-Edwards valve and now centers on valve therapies and related diagnostics to treat heart disease. It differentiates itself by specializing in valve technologies and transcatheter approaches, backed by a track record of clinical leadership and global reach. The goal is to improve patient outcomes by providing safer, less invasive valve treatment options for people around the world.

Company Size

10,001+

Company Stage

IPO

Headquarters

Irvine, California

Founded

1958

Get referred to Edwards Lifesciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CMS finalized expanded TAVR coverage September 10, 2026, enlarging addressable Medicare volume.
  • Q2 2026 sales rose 13.6% to $1.74 billion; management raised full-year guidance.
  • AUTUS approval and ECLIPTIS launch broaden growth beyond mature TAVR programs.

What critics are saying

  • FTC settled July 2026 JC Medical charges for $10 million and compliance oversight.
  • January 2026 injunction blocked JenaValve buyout, crippling Edwards' aortic-regurgitation acquisition strategy.
  • AtriaCure, Medtronic, and Boston Scientific attack Edwards' adjacencies; failure here destroys diversification.

What makes Edwards Lifesciences unique

  • Edwards owns SAPIEN TAVR leadership and the 2025 asymptomatic-label exclusivity.
  • AUTUS, approved October 1, 2026, creates a pediatric pulmonary-valve franchise.
  • ECLIPTIS, cleared July 2026, extends Edwards into surgical stroke-prevention during cardiac surgery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

10%

2 year growth

10%
Business Insider
Oct 2nd, 2026
Edwards Lifesciences (EW) receives a Buy from RBC Capital.

Edwards Lifesciences (EW) receives a Buy from RBC Capital. Oct. 2, 2026, 09:46 PM RBC Capital analyst Kendall Au maintained a Buy rating on Edwards Lifesciences on October 1 and set a price target of $110.00. The company's shares closed yesterday at $85.19. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. According to TipRanks, Au has an average return of -3.6% and a 22.22% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edwards Lifesciences with a $103.40 average price target, representing a 21.38% upside. In a report released on September 28, Leerink Partners also reiterated a Buy rating on the stock with a $101.00 price target. Based on Edwards Lifesciences' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.74 billion and a net profit of $241.9 million. In comparison, last year the company earned a revenue of $1.53 billion and had a net profit of $329.8 million Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in August 2026, Annette Bruls, the CVP, EMEACLA of EW sold 2,644.00 shares for a total of $237,907.12. Read More on EW:

Business Wire
Oct 1st, 2026
Edwards Lifesciences wins FDA approval for AUTUS, first surgical pulmonary valve for pediatric patients

Edwards Lifesciences has received FDA approval for the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for paediatric patients with congenital heart disease. The valve can be expanded as a child grows through a minimally invasive transcatheter procedure, potentially reducing the need for repeat open-heart surgeries. The approval was based on a pivotal study that met its primary safety and effectiveness endpoints. All patients were free from device-related complications through 30 days, with no valve reinterventions through six months. Patients who completed one-year follow-up showed consistent outcomes with favourable valve performance. The AUTUS valve previously received FDA Breakthrough Device designation for addressing an important unmet need in paediatric cardiac care.

Yahoo Finance
Sep 8th, 2026
Edwards Lifesciences beats Q2 expectations, raises 2026 guidance despite lagging Dow by 5.7%

Edwards Lifesciences, an Irvine, California-based cardiovascular products company, has underperformed the Dow Jones Industrial Average in recent months. The stock is down 6.6% from its 52-week high of $96.29 reached on 7 July. Over the past three months, Edwards Lifesciences shares grew 2.8%, lagging the Dow's 3.5% gain. The 52-week performance shows similar underperformance, with the stock up 11.4% compared to the Dow's 17.1% increase. Despite this, the company reported strong Q2 results on 23 July, with net sales rising 13.6% year-over-year to $1.7 billion. Adjusted earnings per share of $0.78 beat Wall Street estimates. The company raised its 2026 sales growth guidance to 10-11% from 9-11% previously. Analysts maintain a "strong buy" consensus rating, with a mean price target suggesting 13.5% upside potential.

BioPharma Watch
Sep 2nd, 2026
Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit.

Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit. Key Takeaway: Edwards Lifesciences Corporation will present at the Deutsche Bank Healthcare Summit on September 16, 2026. CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. A live webcast of the presentation will be available on their investor relations website. Market sentiment analysis. Positive factors. * Edwards Lifesciences is actively engaging with investors. * Participation in a prominent healthcare summit highlights company visibility. * CEO and CFO are presenting, indicating strong leadership presence. IRVINE, Calif.-(BUSINESS WIRE)-Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl Frequently asked questions. When will Edwards Lifesciences present at the summit? Edwards Lifesciences will present on September 16, 2026. Who will represent Edwards Lifesciences at the summit? CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. Is there a webcast available for the presentation? Yes, a live webcast will be available on their investor relations website.

DealLawyers.com
Aug 31st, 2026
Antitrust: KKR agrees to record settlement of HSR non-compliance claims.

Antitrust: KKR agrees to record settlement of HSR non-compliance claims. August 31, 2026 Last year, DealLawyers blogged about the DOJ's decision to file a lawsuit against KKR, in which it alleged that the buyout giant engaged in multiple failures to comply with the HSR Act's pre-merger notification requirements. Last week, the parties filed a proposed settlement of that lawsuit with the SDNY. This excerpt from a White & Case memo summarizes the terms of the settlement: On Wednesday, August 26, 2026, the DOJ filed a proposed settlement requiring KKR & Co. Inc. to pay a civil penalty of $250 million, more than 20 times any prior HSR penalty obtained by the DOJ. Associate Attorney General Stanley Woodward indicated that this proposed settlement "sends a powerful message" and shows that the DOJ "is committed to vigorous enforcement of the Act." This settlement comes after the DOJ alleged in January 2025 that the private equity sponsor "repeatedly violated the HSR Act" through "systemic" violations. Key allegations in the DOJ's complaint included: - Failure to submit responsive business documents required under Item 4 of the HSR Form - Altering or removing content and pages in final Item 4 documents before submission to the FTC/DOJ as part of required HSR filings - Failure to make HSR filings before consummating reportable transactions The memo quotes a KKR spokesperson as saying that the organization determined that continuing the litigation would be a distraction to the organization & that KKR was pleased to put the litigation behind it. They also noted that their investors wouldn't feel the bite, because KKR "will be fully reimbursed by outside law firms." Yikes!!! The settlement comes on the heels of last month's settlement of the FTC's actions targeting Edwards Lifesciences & Genesis Medtech's for alleged violations of the HSR Act. At the time, the $12 million fine that the companies agreed to pay was the largest ever for failing to make an HSR filing. I guess records were made to be broken. - John Jenkins